UNSPSC 51422326: Betamethasone dihydrogen phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H30FO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJO1F9W10R, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(phosphonooxy)-, (11.beta.,16.beta.)-, but more generally known as betamethasone dihydrogen phosphate, which bears US NIH Compound Identifier 107782.

UNSPSC 51422326 Betamethasone dihydrogen phosphate is a Commodity code for a specific corticosteroid pharmaceutical product, but recent state and local procurement activity under this code shows a mismatch with its nominal scope. The two most recent opportunities posted under this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Texas HHS Commission RFI for direct-to-manufacturer prescription program capabilities—involve broader pharmaceutical procurement and pharmacy benefit management rather than betamethasone dihydrogen phosphate itself. The actual work being solicited reflects state and local health departments and HHS agencies purchasing pharmaceutical supplies, pharmacy services, and prescription fulfillment infrastructure to support community health and employee benefit programs.

Geographic activity centers on Florida and Texas based on recent postings, though the Texas opportunity is exploratory in nature (an RFI issued April 3, 2026, with no commitment timeline). The Seminole County IFB, posted June 30, 2026, with a response deadline of July 26, 2023, sought annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems for quarterly delivery to the Seminole County Community Health Building, with vendors responsible for shipping costs and required to meet E-Verify, drug-free workplace, and insurance coverage requirements. The code shows limited recent activity aligned to its specific pharmaceutical commodity—the posted opportunities reflect state and local governments buying pharmaceutical supplies and pharmacy program infrastructure broadly rather than betamethasone dihydrogen phosphate as a discrete product line.